Keywords: American Diabetes Association meeting, Booehringer Ingelheim, Linagliptin, Bristol-Myers Squibb, AstraZeneda, Onglyza

Strong date from Boehringer Ingelheim and Bristol-Myers/AstraZeneca on diabetes drugs presented at ADA

Article | 29 June 2010

Print This

Continuing the string of positive news on diabetes drug developments at the ongoing 70th Scientific Sessions of the American Diabetes ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in